Entrar Registro gratuito

AC Immune SA Propriedade de acionista maioritário

Qual é o Propriedade de acionista maioritário de AC Immune SA?

O Propriedade de acionista maioritário de AC Immune SA é 47.74%

Qual é a definição de Propriedade de acionista maioritário?



A propriedade de acionistas maioritários é calculada como o número total de ações pertencentes aos acionistas maioritários (acionistas que possuem mais de 5% da corporação ou um executivo ou diretor da empresa) dividido pelo total de ações em circulação.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Propriedade de acionista maioritário de empresas na Setor Health Care em NASDAQ em comparação com AC Immune SA

O que AC Immune SA faz?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Empresas com propriedade de acionista maioritário semelhantes a AC Immune SA